AG
CTIC

Aperio Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Aperio Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,871
Closed -$10K – 2091
2016
Q1 		$10K Buy
+1,871
New +$15K ﹤0.01% 2020
2015
Q3 		– Sell
-1,004
Closed -$20K – 2100
2015
Q2 		$20K Buy
+1,004
New +$19.4K ﹤0.01% 2000

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Aperio Group's CTIC Position: Q2 2016 in Review

Aperio Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2016, closing a stake of 1,871 shares — an estimated $10K sold.

Aperio Group first reported a position in CTIC in Q2 2015 and held it in 2 quarters. The position peaked at $20K in Q2 2015. 67 funds tracked by Wall St. Rank hold CTIC as of Q2 2016.

  • Aperio Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2016 after selling out during the quarter.
  • Aperio Group sold 1,871 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2016, an estimated $10K.
  • Aperio Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2015 and held it in 2 quarters.
  • Aperio Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $20K in Q2 2015.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2016.

Based on Aperio Group's 13F filing for Q2 2016, filed 12 Aug 2016.